Europe Clinical Trials Market

Europe Clinical Trials Market Size (2024 to 2032)

The Clinical Trials Market in Europe was valued at USD 6.37 Billion in 2023 and is projected to reach USD 11.72 Billion by 2032 from USD 6.82 billion in 2024, growing at a CAGR of 7% from 2024 to 2032.

Clinical laboratories conduct many experiments to determine new products, including finding new treatment procedures for various procedures, known as clinical trials. These products ensure the safety and efficacy of the new product. They are generally responsible for producing quality drugs and vaccines that are concerned about people's health. In addition, while observing the product manufactured, investigators will perform many tests to find out errors in the design.

The clinical trials market in Europe has been growing rapidly. Looking at the current scenario, the COVID-19 pandemic is highly affecting the clinical trial market in Europe. Germany holds the highest number of clinical trials in Europe because of low research and development costs. The number of people infected with COVID-19 is increasing tremendously, which is a significant factor in the market's growth. Italy has one of the worst COVID-19 outbreaks in the world. Clinical trials are ongoing to develop a vaccine against COVID-19. However, other trials like oncology are delayed. Spain has also been adversely affected by this pandemic and is leveling up its market growth. The UK is officially the worst-hit country in Europe. The government, market participants, and research organizations are working together to develop a vaccine against COVID-19. France was also leading the market, but the current challenges of running clinical trials safely and effectively hinder the growth of this region's clinical trials market.

Collaborations between key players to enhance research and development activities and deliver high-quality products are prompting market share growth. Pharmaceutical and biopharmaceutical companies focus on developing comprehensive integrated or functionally outsourced services that emphasize drug discovery. In addition, the rising prevalence of treating cancer patients with advanced treatment procedures is leveraging the market's growth rate. In Europe, Cancer is one of the major concerns for causing death and increasing the morbidity rate. Around 1.9 million people die due to cancer disease every year, and 3.7 million new cases register only in Europe. These statistics greatly enhance the demand for clinical trials to launch novel drugs. Also, increasing government support through investments in pharmaceutical companies is leveling up the market size. Government authorities play an important role in regulating the safety and efficacy of new drugs, and their guidance will help companies promote high-quality medical treatment procedures.

The trend toward adopting precision medicine is estimated to elicit lucrative growth opportunities for the European clinical trials market. Precision medicine is the most trending while manufacturing new drugs. Precision medicine made it easy to perform clinical trials on individual patients for a specific period rather than following the traditional clinical trial method. Traditional clinical trials were performed on thousands of individuals to determine the effect of the drug being manufactured. Due to this factor, only a few drugs are used to pass all the phases. In contrast, precision medicine allows the use of pharmacogenetics, which increases the number of drugs that are quickly developing.

On the down side, the lack of experienced scientists from the pharmaceutical, biopharmaceutical, and medical device fields is majorly restraining the growth rate of the European clinical trial market. Skilled people are needed to develop innovative drugs to enhance their quality. Contract research organizations (CROs) are facing difficulty recruiting these people due to financial issues. Also, the high cost of the development of new drugs is another attribute ascribed to hinder the market growth rate. Less availability of raw materials is a major constraint for the increasing cost of the final outcomes. Increasing safety concerns among the public for newly launched products is posing a big challenging factor for the key players. Along with this, poor infrastructure in developing countries is acting as a barrier to the growth of the market during the forecast period. 

This research report on the European clinical trials market has been segmented into the following categories

Europe Clinical Trials Market Analysis By Phase

• Phase I
• Phase II
• Phase III

Europe Clinical Trials Market Analysis By Design

• Interventional Trials
• Observational Trials
• Expanded Access Trials

Europe Clinical Trials Market Analysis By Indications

• Autoimmune
• Blood disorders
• Cancer
• Circulatory
• CNS
• Congenital
• CVS
• Dermatology
• Ear
• Gastrointestinal
• Genitourinary
• Infections
• Mental disorders
• Metabolic
• Musculoskeletal
• Nose
• Ophthalmology  

Europe Clinical Trials Market Analysis By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, Europe was the second biggest market in terms of market share in the global clinical trials market in 2023. In Europe, the clinical trials market in the UK had the most significant share in 2023 and is also to continue the same in the forecast period. More than 600 commercial clinical trials are taking place in the NHS (National Health Service). The UK is one of the leading countries in research for heart diseases, immunology, and nervous system conditions. Patients in the UK voluntarily take part in clinical trials. Around 870250 people take part in commercial and non-commercial clinical trials. The government is also increasing funds for new research and clinical trials. For example, the UK government has launched a new clinical trial program to fast-track the development of new drugs to treat COVID-19 named ACCORD. The recovery trial in the UK is currently the largest randomized clinical trial in the world.

The German clinical trials market is anticipated to grow at a steady CAGR during the forecast period. Germany has the highest number of clinical trials in Europe because of the low cost. The pharmaceutical industry in Germany is highly engaged in research and development; more than 70% of clinical trials have support from a government organization. The Federal Ministry of Education and Research has launched a Pharmaceutical Initiative for Germany to promote research and development activities. BioNTech and Pfizer have secured approval from German regulatory authorities to conduct phase I / II clinical trials of COVID-19 vaccines.

With the growing number of clinical trials, the market in Spain is anticipated to grow at a moderate CAGR during the forecast period. Spain ranks fourth in Europe in conducting the number of clinical trials in 2019. The Spanish government is starting a new division for clinical trials. Spain is involved in 18% of the total clinical trials in Europe. PharmaMar, a Spanish company, has started phase II clinical trials of a drug named aplidin to treat COVID-19. 

The clinical trials market in France is expected to have a healthy CAGR in the coming years. The French government invests a significant amount in clinical trials. In addition, ongoing research on developing drugs for rare diseases is enhancing the market's growth rate. For example, clinical trials of Ivermectin to treat COVID-19 have already started.

KEY MARKET PLAYERS

Companies that play a significant role in the Europe clinical trails market profiled in this report are Chiltern, Omnicare, PPD, Parexel, Kendle, Quintiles, ICON Plc, and Charles River.